Department of Medicine 1, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Deutsches Zentrum Immuntherapie (DZI), University Hospital Erlangen, Erlangen, Germany.
Gut. 2024 Jan 5;73(2):282-297. doi: 10.1136/gutjnl-2023-329628.
We sought to investigate the role of interleukin (IL)-20 in IBD and experimental colitis.
Experimental colitis was induced in mice deficient in components of the IL-20 and signal transducer and activator of transcription (STAT)2 signalling pathways. In vivo imaging, high-resolution mini-endoscopy and histology were used to assess intestinal inflammation. We further used RNA-sequencing (RNA-Seq), RNAScope and Gene Ontology analysis, western blot analysis and co-immunoprecipitation, confocal microscopy and intestinal epithelial cell (IEC)-derived three-dimensional organoids to investigate the underlying molecular mechanisms. Results were validated using samples from patients with IBD and non-IBD control subjects by a combination of RNA-Seq, organoids and immunostainings.
In IBD, levels were induced during remission and were significantly higher in antitumour necrosis factor responders versus non-responders. IL-20RA and IL-20RB were present on IECs from patients with IBD and IL-20-induced STAT3 and suppressed interferon (IFN)-STAT2 signalling in these cells. In IBD, experimental dextran sulfate sodium (DSS)-induced colitis and mucosal healing, IECs were the main producers of IL-20. Compared with wildtype controls, and mice were more susceptible to experimental DSS-induced colitis. IL-20 deficiency was associated with increased IFN/STAT2 activity in mice and IFN/STAT2-induced necroptotic cell death in IEC-derived organoids could be markedly blocked by IL-20. Moreover, newly generated mice, lacking STAT2 in IECs, were less susceptible to experimental colitis compared with wildtype controls and the administration of IL-20 suppressed colitis activity in wildtype animals.
IL-20 controls colitis and mucosal healing by interfering with the IFN/STAT2 death signalling pathway in IECs. These results indicate new directions for suppressing gut inflammation by modulating IL-20-controlled STAT2 signals.
我们旨在研究白细胞介素(IL)-20 在炎症性肠病(IBD)和实验性结肠炎中的作用。
采用缺乏 IL-20 和信号转导和转录激活因子(STAT)2 信号通路成分的小鼠诱导实验性结肠炎。采用体内成像、高分辨率微型内镜和组织学检查来评估肠道炎症。我们进一步使用 RNA 测序(RNA-Seq)、RNAScope 和基因本体分析、Western blot 分析和共免疫沉淀、共聚焦显微镜和肠上皮细胞(IEC)衍生的三维类器官来研究潜在的分子机制。使用 IBD 患者和非 IBD 对照患者的样本通过 RNA-Seq、类器官和免疫染色相结合的方法来验证结果。
在 IBD 中, 水平在缓解期被诱导,并且在抗肿瘤坏死因子反应者与无反应者之间存在显著差异。IL-20RA 和 IL-20RB 存在于 IBD 患者的 IEC 上,并且 IL-20 诱导了这些细胞中的 STAT3 和抑制了干扰素(IFN)-STAT2 信号。在 IBD 中,实验性葡聚糖硫酸钠(DSS)诱导的结肠炎和黏膜愈合中,IEC 是 IL-20 的主要产生者。与野生型对照相比, 和 小鼠更容易发生实验性 DSS 诱导的结肠炎。IL-20 缺乏与小鼠中 IFN/STAT2 活性增加有关,并且 IFN/STAT2 诱导的 IEC 衍生类器官中的细胞坏死可被 IL-20 显著阻断。此外,与野生型对照相比,缺乏 IEC 中 STAT2 的新型 小鼠对实验性结肠炎的易感性降低,并且 IL-20 的给药抑制了野生型动物的结肠炎活动。
IL-20 通过干扰 IEC 中的 IFN/STAT2 死亡信号通路来控制结肠炎和黏膜愈合。这些结果为通过调节 IL-20 控制的 STAT2 信号来抑制肠道炎症提供了新的方向。